Published in Cancer Weekly, August 1st, 2000
This investigational study will examine the safety and efficacy of G3139 combined with dacarbazine (DTIC). The trial, sponsored by Genta, Inc., will involve major cancer centers and oncology practices in North America and Europe.
At the Annual Meeting of the American Association for Cancer Research, held in San Francisco, California, during April 2000, Dr. Burkhard Jansen from the University of Vienna...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.